Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy
This article was originally published in The Pink Sheet Daily
Parallels to Novartis-Sandoz 2005 combination seen.
You may also be interested in...
"It's hard to see how Pfizer would run the company," one analyst said in an interview.
Daiichi will pay $4.6 billion for stake in generics marketer.
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.